[go: up one dir, main page]

PE20091726A1 - PROPAGATION OF ORTHOMIXOVIRIDAE - Google Patents

PROPAGATION OF ORTHOMIXOVIRIDAE

Info

Publication number
PE20091726A1
PE20091726A1 PE2008001863A PE2008001863A PE20091726A1 PE 20091726 A1 PE20091726 A1 PE 20091726A1 PE 2008001863 A PE2008001863 A PE 2008001863A PE 2008001863 A PE2008001863 A PE 2008001863A PE 20091726 A1 PE20091726 A1 PE 20091726A1
Authority
PE
Peru
Prior art keywords
virus
orthomixoviridae
tipo
family
influentza
Prior art date
Application number
PE2008001863A
Other languages
Spanish (es)
Inventor
Carla Christina Schrier
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of PE20091726A1 publication Critical patent/PE20091726A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C12N2710/16164—Methods of inactivation or attenuation by serial passage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16051—Methods of production or purification of viral material
    • C12N2760/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

REFERIDA A UN METODO PARA PROPAGAR EL VIRUS DE LA FAMILIA ORTOMIXOVIRIDAE MEDIANTE UNA LINEA CELULAR Mpf DE HURON QUE TIENE UN NUMERO CROMOSOMICO DE 2N=38, DONDE DICHO VIRUS DE LA FAMILIA ORTOMIXOVIRIDAE ES UN VIRUS INFLUENZA TIPO A, B O C, PREFERENTEMENTE, TIPO A O B Y DONDE DICHO METODO CONSITE EN LA INFECCION DE UNA LINEA CELULAR DE HURON CON EL VIRUS DE LA FAMILIA ORTOMIXOVIRIDAE Y LA POSTERIOR COSECHA DE LA PROGENIE VIRALREFERRED TO A METHOD TO PROPAGATE THE VIRUS OF THE ORTHOMIXOVIRIDAE FAMILY BY MEANS OF A HURON Mpf CELL LINE THAT HAS A CHROMOSOMIC NUMBER OF 2N = 38, WHERE SAID VIRUS OF THE ORTHOMIXOVIRIDAE FAMILY, DOCYTOMIXOVIRIDAE VIRUS TIPO AIPO BOCERZA PREYTOBERZA INFLUENTZA TIPO BOCERZA TIPO INFLUENTZA INFLUENT VIRUS SAID METHOD CONSISTS IN THE INFECTION OF A HURON CELL LINE WITH THE VIRUS OF THE ORTHOMIXOVIRIDAE FAMILY AND THE SUBSEQUENT HARVEST OF THE VIRAL PROGENIE

PE2008001863A 2007-11-02 2008-10-30 PROPAGATION OF ORTHOMIXOVIRIDAE PE20091726A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98478407P 2007-11-02 2007-11-02
EP07119867 2007-11-02

Publications (1)

Publication Number Publication Date
PE20091726A1 true PE20091726A1 (en) 2009-11-13

Family

ID=39722699

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001863A PE20091726A1 (en) 2007-11-02 2008-10-30 PROPAGATION OF ORTHOMIXOVIRIDAE

Country Status (5)

Country Link
AR (1) AR069142A1 (en)
PE (1) PE20091726A1 (en)
TW (1) TW200936758A (en)
UY (1) UY31449A1 (en)
WO (1) WO2009056628A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006880A1 (en) * 2009-07-14 2011-01-20 Intervet International B.V. Lawsonia intracellularis propagation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2723740B1 (en) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc PROCESS FOR THE PREPARATION OF INFLUENZA VIRUS ANTIGENS, ANTIGENS OBTAINED AND THEIR APPLICATIONS
US6743631B1 (en) * 1998-03-17 2004-06-01 North Shore University Hospital Research Corporation Use of human serum resistant vector particles and cell lines for human gene therapy

Also Published As

Publication number Publication date
AR069142A1 (en) 2009-12-30
TW200936758A (en) 2009-09-01
WO2009056628A1 (en) 2009-05-07
UY31449A1 (en) 2009-05-29

Similar Documents

Publication Publication Date Title
CL2020000685A1 (en) Substituted nucleosides, nucleotides and analogs thereof.
CL2008003794A1 (en) Genetically modified vesicular stomatitis virus (vsv) comprising at least one amino acid mutation in a region of some of the m, g and l proteins of the virus; method to produce it; immunogenic composition comprising it; method of adapting a virus in a cell culture.
CR9076A (en) METHOD AND MATERIALS TO CONFERENCE RESISTANCE TO PLANT PESTS AND PATHOGENS
CO6410304A2 (en) COMBINATION OF A NUCLEOSIDE POLYMERASE INHIBITOR WITH A MACROCYCLY PROTEASE INHIBITOR AND ITS USE IN THE TREATMENT OF HEPATITIS C, HEPATIC FIBROSIS AND ALTERED HEPATIC FUNCTION
EA200970996A1 (en) STEM CELL LINES OBTAINED FROM DUCK EMBRYOS FOR VIRAL VACCINES PRODUCTION
MX2012002365A (en) Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses.
PE20120571A1 (en) PRODUCTION OF ELEVATED TITLES OF POLIVIRUS FOR VACCINE PRODUCTION
AR079504A1 (en) COMBINED USE OF VIP 3AB AND CRY1FA FOR HANDLING RESISTANT INSECTS
UY33667A (en) ANTIVIRAL COMPOUNDS
CL2009002207A1 (en) Compounds derived from 3-hydroxy-5- (9h-purin-9-yl) tetrahydrofuran-2-yl, an inhibitor of the replication of arn-dependent viral arn; pharmaceutical composition; use for the treatment of hepatitis c.
CO6270240A2 (en) Double-stranded RNA with modified lipid that has a powerful RNA interference effect
AR079505A1 (en) USE OF CRY1DA IN COMBINATION WITH CRY1CA FOR THE MANAGEMENT OF RESISTANT INSECTS
UY32699A (en) EFFECTIVE ANTIVIRAL COMPOUNDS TO INHIBIT THE REPLICATION OF HEPATITIS C VIRUS ("HCV"), PROCESSES, COMPOSITIONS, AND RELATED METHODS
CL2008003020A1 (en) Method for producing the attenuated vesicular stomatitis virus (vsv), which comprises generating cells that express the vsv protein g from an optimized vsv gene, infecting said cells with the attenuated vsv, and recovering the viruses from culture; composition comprising the attenuated virus and kit to produce the virus.
EA200870304A1 (en) PSEUDOINFECTIONAL FLAVIVIRUS AND ITS APPLICATION
GT200900097A (en) INHIBITORS OF HCV PROTEASE NS3.
BR112017007431A2 (en) hybrid long fiber thermoplastic composites
CL2008003821A1 (en) Method for producing attenuated vesicular stomatitis virus (vsv) in cells, comprising: a) providing a cell comprising an optimized and inducible g vsv gene, b) inducing the cell to express said gene, c) infecting the cell with an attenuated vsv, d) grow these cells, and e) recover the attenuated vsv
ECSP20084442A (en) SUBSTITUTED THIOPHENOCARBOXAMIDES AND ANALOGUES THEREOF
CL2015003388A1 (en) Modular architecture construction system with universal and interchangeable parts.
MX387420B (en) VIRUS PRODUCTION IN CELL CULTURES.
CR20160178A (en) DEOXINOJIRIMICINE DERIVATIVES AND THEIR METHODS OF USE
CO2021013970A2 (en) Multi-respiratory virus antigen-specific t cells and methods for making and using the same therapeutically
AR117877A1 (en) RECOMBINANT RHABDOVIRUS CODING CCL21
MX2020004063A (en) Systems and methods to produce b cells genetically modified to express selected antibodies.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal